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Sinmary In a study of 29 patients who were receiving or had received interferon b (IFN-b) as
maintenance therapy for multiple myeloma, antibodies were detected in 58% (17 29) of patients measured by a
solid-phase enzyme-linked immunosorbent assay (ELISA). Only 7 17 patients who were positive for antibody
in the ELISA had neutralising antibody to IFN-zb, measured by virus growth inhibition. These patients
comprised six who were receiving IFN-ab at the time of assessment and one who had finished treatment.
Among patients who were receiving the cytokine. four had progressive disease, one was in complete remission
and one in partial remission. Neutralising activity was also detected to natural human leucocyte IFN--a in the
same patients. Two patients who were positive for neutralising antibody remain in remission and are
continuing to receive IFN-a:b. These two patients have since lost their neutralising titre. No neutralising
antibody to IFN-a2b or natural human leucocyte IFN-x was detected in serum from six normal donors. The
data suggest that neutralising antibody formation in patients with multiple myeloma is not responsible for
relapse in patients receiving IFN-M2b. The transient nature of neutralising antibody production in patients who
remain in remission suggests that this response to IFN-mb is not associated with memory B cells.
Interferons are a heterogeneous family of proteins which
have pleiotropic biological effects in addition to their specific
antiviral activity. The availability of highly purified human
leucocyte interferon (IFN-x) and the development of recom-
binant products has made it possible to explore the potential
therapeutic benefits of these molecules in the treatment of
cancer (Mellstedt et al., 1979; Gutterman et al., 1980).
In untreated patients with multiple myeloma, IFN-a used
as a single agent has been shown to achieve a response rate
of 20-30% (Ahre et al., 1984). Similar response rates have
been achieved in patients with advanced multiple myeloma
refractory to cytotoxic chemotherapy or in relapse (Costanzi
et al., 1985; Rodjer et al., 1990). Addition of IFN-x to
conventional induction therapy has increased progression-
free survival (IFN-a2b: Ludwig et al., 1991; Westin et al.,
1991) and response frequency (natural IFN-a: Mellstedt et
al.. 1991: Osterborg et al.. 1993) in previously untreated
patients. However, in a small non-randomised study there
was no significant difference in survival duration between
patients given conventional chemotherapy with or without
natural leucocyte IFN (Umeda et al., 1991).
Recent studies have concentrated on the use of IFN-zs as
maintenance therapy for multiple myeloma. Intensification of
maintenance therapy with glucocorticoids and IFN-a2b fol-
lowing conventional chemotherapy induced a further reduc-
tion of the M component in 50% of patients who responded
to chemotherapy (Palumbo et al., 1992). Among 41 patients
who failed to achieve remission with chemotherapy, 32%
achieved at least a partial response with IFN/dexamethasone,
and 42% who had responded to induction showed a further
reduction in tumour burden (Salmon et al., 1991). In a
non-randomised study, the efficacy of maintenance therapy
with recombinant IFN-a2b alone was dependent on the re-
sponse to intensive therapy with high-dose melphalan
(HDM) and total body irradiation. Amongst patients who
achieved complete remission (CR) the probability of
progression-free survival at 33 months was significantly
greater than that for patients who achieved partial response
(PR) (Attal et al., 1992). In an ongoing randomised study of
84 patients at the Royal Marsden Hospital, recombinant
IFN-eb increased the median progression-free survival fol-
lowing intensive chemotherapy with HDM and autologous
bone marrow rescue (ABMR) (Cunningham et al.. 1993). In
62 84 of these patients who achieved CR to HDM ABMR,
IFN-a:b induced a significant prolongation of remission. and
53% of patients remain in stable CR 4 years after intensive
therapy. However, among patients who achieved only a par-
tial response or who failed to respond to HDM ABMR,
IFN-alb failed to prolong progression-free survival. These
studies suggest that the efficacy of IFN-as as a maintenance
therapy for multiple myeloma is greatest when there has been
a significant reduction of the tumour burden.
In vitro IFN-a reduced the proliferation of a myeloma cell
line at clinically achievable drug concentrations (80-
800 U ml-') and acted synergistically with vinblastine and
cisplatin (Aapro et al., 1983). However, it is not known
whether IFN-ms are cytostatic or cytotoxic to myeloma cells
in vivo or whether they exert their effect(s) directly by
inhibiting the proliferation of residual tumour cells or by
modulation of the host response. Furthermore, it is not
known whether refractiveness to maintenance therapy or re-
lapse in patients receiving IFN-oxs is associated with the
formation of neutralising antibodies to the compound(s).
The development of neutralising antibodies is likely to be
dependent on the length of treatment and/or higher doses of
IFNs, both of which will contribute to the increased
cumulative dose of protein. The route of administration
(Konrad et al., 1987), the underlying disease (particularly
with regard to the state of immune system) and the source of
protein may also contribute to antibody formation. In addi-
tion to the development of neutralising antibodies in re-
sponse to therapy with natural or recombinant molecules,
autoantibodies to natural leucocyte IFN have been found in
patients with autoimmune disease (Panem et al., 1982), in
cancer patients before treatment with IFN-a (Trown et al..
1983) and in sera from normal donors (Ross et al., 1990). In
multiple myeloma, which is characterised by immune sup-
pression, some restoration of normal immunoglobulin func-
tion occurs following response to treatment, however it is not
known whether patients can produce a sustainable response
to antigen and consequently whether the development of
neutralising antibodies to IFN-a is involved in relapse or
refractoriness to further treatment in this disease.
In this report. we set out to determine whether patients
with multiple myeloma receiving maintenance therapy with
IFN--Xb develop antibodies to the cytokine which are
associated with relapse and whether autoantibodies to human
leucocyte IFN-a are present in serum.
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Materals and methods
Clinical samples
Patients and donors gave informed consent for blood
samples to be taken. Peripheral blood samples were collected
by venepuncture from multiple myeloma patients and normal
donors at out-patient clinics or as in-patients undergoing
treatment. Wherever possible, patients were requested to
undergo venepuncture at 3 monthly intervals during treat-
ment with IFN-ab. Serum samples were separated within 2 h
of collection. Amongst patients receiving IFN-a2b, blood
samples were taken within 24 h of drug administration.
Patients with multiple myeloma who presented at the
Royal Marsden Hospital, Sutton, received one of two condi-
tioning regimens, either CY-VAMP [i.v. infusion of vincnrs-
tine, 0.4 mg, and adriamycin, 9 mg m-2, over 24 h for 4 days
with bolus of methylprednisolone (1.5 g i.v. or orally daily
for 5 days) plus cyclophosphamide (500 mg i.v. bolus on days
1, 8 and 15)] or VERCY-VAMP [vincristine, adriamycin,
methylprednisolone and cyclophosphamide (doses as before)
plus verapamil (10 mg i.v. over 24 h for 5 days)] followed by
HDM (either 200 mg m-2 with ABMR or 140 mg m-2 alone).
Patients were given IFN-a2b (INTRON A, Shering-Plough) at
3 x 106 U m2' subcutaneously three times weekly when the
leucocyte count was greater than 3 x 1091' and platelets
were greater than 100 x 1091-'. Among the group of
patients. 12 were receiving IFN-a2b as part of the ongoing
randomised study. Patients were designated to receive a
second course of IFN-a2b if there was a break in therapy
greater than 2 weeks not associated with relapse. Eight
patients who fulfilled this criterion had had treatment with
IFN-2b interrupted for between 2 weeks and 5 months. One
patient who had relapsed during treatment with IFN-a2b was
given further intensive therapy followed by IFN-a,b after an
interval of 26 months.
Clinical status
A complete remission (CR) was defined as the absence of
measurable paraprotein and bone marrow infiltration by
myeloma cells of <5%. A partial response (PR) was defined
as a paraprotein level reduced by 50% and improvement in
all other clinical features sustained for longer than I
month.
Assayfor IFN antibodies
Serum samples were stored at -20°C and were heat inacti-
vated at 56°C for 30 min before being analysed. They were
assayed for anti-IFN-a, antibodies by two different
methods.
The presence of binding antibodies to IFN-a2b was
measured using a solid-phase enzyme-linked immunoassay
(ELISA) (Anawa Labs, Zurich, Switzerland). The assay uses
beads coated with recombinant IFN-a2 (rIFN-a2), which were
incubated with the serum samples for 24 h at 4C. The
anti-IFN-a2 antibodies in the serum were captured by the
beads and, after washing, incubated at 40C for 24 h with
rIFN-a2-peroxidase conjugate. After washing, the enzyme
activity on the beads was measured by incubation with
enzyme substrate (tetramethylbenzidine) and measurement of
the optical density at 450 nm. Human serum with known
amounts of rabbit antibody to rIFN--, was used as a stan-
dard for the calibration curve over the range of 0 to 10
(arbitrary) units ml-. The specificity of the signal obtained
with patients' sera was checked with the confirmatory test to
exclude false-positive results. In the confirmatory test, the
signal of antibody-positive sera was depressed by addition of
free rIFN-a2, whereas non-specific binding was not sup-
pressed by the addition of free IFN-,.
The IFN neutralisation bioassay is based on inhibition by
IFN of viral cytopathic effect (Freund et al., 1989; Ross et
al., 1990). The rationale for the test is that Cocal virus causes
the destruction of cells and the release of infective virion.
Addition of IFN-a to cell monolayers before infection with
virus inhibits viral replication and conserves the viability of
the monolayer. In serum samples which contain antibody to
IFN-a neutralisation of IFN-a before addition to HeLa cell
monolayers reverses the protective effect of IFN-x and results
in destruction of the monolayer by the virus. Cell viability is
assessable by measuring the activity of succinate hydrogenase
in viable cells with the MTT assay.
MTT assay
3-[4.5-Dimethylthiazol-2-vl]-2.5 diphenyl tetrazolium bromide
(MTT Cat. No. M 2128: Sigma. Poole. UK) was dissolved in
phosphate-buffered saline (PBS) at a concentration of
5 mg ml-'. filtered through a sterilising filter and stored at
4'C in a dark bottle. Lysis solution was 12.5% sodium
dodecyl sulphate in 45% dimethyl formamide in water
(analytical grade pH 4.7).
A working solution of MTT was prepared for each experi-
ment consisting of one part MTT to eight parts PBS. A
100p1 volume of this solution was added to microtitre wells
after removal of the challenge virus (see below), after incuba-
tion at 3TC for 2 h, 100p1 of lysis solution was added to
dissolve formazan-protein complexes for 45 min. Optical
density measurements were made in a Titertek 96-well multi-
scanner at 540 nm. using an NMTT lysis solution as blank.
Stock *irus
Confluent monolayers of HeLa cells in 2 x 175 cm2 tissue
culture flasks were infected with Cocal virus (kindly supplied
by W. James. Sir William Dunn School of Pathology,
Oxford. UK) in 10 ml of maintenance medium [c-modifi-
cation of Eagle's medium supplemented with 1% fetal calf
serum (FCS)] and incubated at 37°C for 24 h. The medium.
containing cell debris and virus, was harvested from the
cultures. ultrasonicated for 2 min and filtered through a
0.2 pm filter. Cocal was plaque titrated in HeLa cells before
use in experiments. Stock virus contained 7 x 10' plaque-
forming units (p.f.u.) ml-'. Preliminary experiments were
done to optimise the MIT assay. Virus and IFN-a (IFN-e,b
and natural human leucocyte IFN-a. Cat. no. I 9887. Sigma)
titrations were carried out to establish the minimum concen-
trations of virus that produced the most pronounced change
in optical density (OD) and the minimum concentration of
IFN-a required to reverse the cytopathic effect at 540 nm.
Ninety-six-well microtitre plates were seeded with HeLa cells
at a concentration of 10 cells per well in 100 p1 of RPMI-
1640 medium supplemented with 7.5% FCS. After attach-
ment for 4 h at 37C, 100 p1 of IFN-a was added to give
concentrations between 0.05 and 2.500 units ml-' in main-
tenance medium (see above). Cultures were incubated over-
night. Cocal virus was added in 100 1l of maintenance medium
at doses of 0.07. 0.70 and 7.0 p.f.u. per cell and incubation
continued for 24 h. The medium was discarded into bleach
and I00p1 of MIT (1.25 ngml-') added to each well. After
2 h at 37C. 100p1 of lysis solution was added to each well
and the plate incubated for 45 min before reading at 540 nm
in a Titertek multiscanner. The concentration of Cocal virus
which gave the optimal change in OD signal was 0.07 p.f.u.
per cell. The protective capacity of both human leucocyte
IFN-a and IFN-eb against viral cytopathic effect increased
between doses of 0.25 and 5.0 units ml-' IFN-a and
thereafter remained constant. All tests with patients' sera
were done using IFN-a at a concentration of 5 units ml'
(i.e. I unit per well). Polyclonal rabbit anti-human leucocyte
IFN-<x antibody (r.a-huIFN) was titrated against the optimal
concentration of Cocal and 5 units ml' IFN-a to establish
the sensitivity of the MIT assay with respect to changes in
OD as a function of antibody concentration (Figure 1). Also.
both natural and recombinant IFN-a were titrated against
5 units ml-' r.a-huIFN to determine the sensitivity of the
assay with respect to IFN-x concentration (Figure 2). Both
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Fuwe 1 Sensitivity of the MTIT assay measured at 450 nm
demonstrated by titration of polyclonal rabbit anti-human
leucocyte IFN-a antibody against Cocal virus and 5 unitsml'
IFN-a [both IFN-e2, (A) and natural human leucocyte IFN-4
(0)] Cell control, HeLa cell monolayer alone; CC + IFN, cell
control plus 5 units ml' IFN-; virus control, effect of Cocal





42 samples were taken from patients who were receiving
IFN-a2b at the time of testing and six samples from patients
who had stopped therapy for at least 8 days. The clinical
status of each patient and the isotype of their disease at the
time when the first blood sample was taken are shown in
Table I. During the period of the study there was a change in
clinical status in three patients. Of those patients who were
receiving or had received IFN-a2b, one patient with IgAx
myeloma progressed from CR to progressive disease (PD), as
did another with IgGx myeloma who had been in PR. Subse-
quent samples from both patients during PD were included
in the test. Additionally, a blood sample from a patient with
IgAl myeloma who was in PR 23 months after intensive
therapy was tested I month before the start of maintenance
IFN-a2b therapy and again during IFN-a2b therapy on pro-
gressing to PD.
Nineteen samples from 15 patients who were receiving
IFN-a2b at the time of testing were positive for antibody; 11
had PD, two were in PR and two in CR (Table II). Twenty-
three samples from 17 patients were negative: nine had PD,
six were in PR and two in CR. The median duration of
maintenance therapy in both antibody-positive and -negative
patients was 12 months (range 5-44 months). Also, there
was no significant difference in the distribution of length of
treatment with IFN-M2b between antibody-positive and
antibody-negative patients.
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FgWe 2 Sensitivity of the MTT assay with respect to IFN-z
concentration. Titration of both IFN-m,b (A) and natural human
leucocyte IFN-x (0) against Cocal virus and 5unitsml1' poly-
clonal rabbit anti-human leucocyte IFN-a antibody measured at
450 nm. Cell and virus controls as in Figure 1.
specificity for commercially available antibody to human
leucocyte IFN-a.
Antibodi neutralisation assay
Sera were diluted into maintenance medium (1:1) containing
either 10 units ml-' human leucocyte IFN-a or IFN--b and
incubated in 96-well tissue culture plates (Nunc) at 37C for
1 h. A 100 i1l volume of the contents of each well was trans-
ferred to HeLa cell monolayers in similar plates containing
I04cells per well in 100 JLl of growth medium. The final
concentration of IFN-a before addition of Cocal was 5 units
ml-' (1 unit per well). All subsequent procedures were car-
ried out as described previously. The presence of neutralising
antibody to IFN-a in patients' sera was considered significant
if the mean OD reading from duplicate samples differed by
more than two standard deviations from values at the next
successive dilution of serum.
Results
In the primary screen for antibody to IFN-a2, 48 samples
from 29 patients were tested in the solid-phase ELISA assay;
Table I Isotype and clinical status of patients in study
Clinical statusa
Isot)pe No. ofpatients CR PR PD
IgGC 6 6
IgGic 14 2 6 6
IgDAk I
IgAA 3 1 1 1
IgAx 1 1
BJI 1 I
BJxC 2 1 1
Non-secretory 1 I
3CR, complete remission; PR, partial response; PD. progressive
disease.
Tabe H Serum samples from multiple myeloma patients tested
positive by ELISA for antibodies against interferon-a,
Patient No. ofIFN-ab Duration ofIFN-a? ELISA
no. Isonype courses courses (months) (ImP- I
Mveloma patients receiving IFN-a2 treatment at time ofsample
1 IgG. 2 4+8 <1.0
2 IgGk 1 26 1.3
3 IgGO 1 10 <1.0
4 IgG. 1 32 <1.0
5 IgGx 2 1+13 7.4
2 1+15 3.2
6 IgAI 1 12 1.0
7r IgGP 1 12 4.0
2 23+10 5.5
2 23+12 8.2
8 IgGO 2 2+ 14 3.4
9 IgAic 1 5 <1.0
1 7 <1.0
10b IgGic 1 31 <1.0
11 IgDA 1 44 <1.0
12a IgGx 1 44 7.6
13b B.Jc 1 12 10.1
14 Non-secretory 2 5+9 8.7
15 IgGx 2 26+11 12.5
Mveloma patients not receiving IFN-a treatment at time ofsample
l0" IgGx 1 34 <1.0
1 34 <1.0
16d IgGA 2 19 + 5 <1.0
All samples taken from patients in PD except for: apatients in CR;
'patientsinPR.cSample taken 1 and2monthsafterlastdoseofIFN-a.b.
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(no. 7) who remains in CR had detectable antibody during
the first course of treatment which continued for 23 months,
and the amount of antibody increased during the second
course. A second patient (no. 12) who remains in CR has
been on maintenance therapy with IFN-a2b for 44 months
with a high titre of antibody. Among five patients who had
not received IFN-a2b for at least 8 days, antibodies were
detected in one patient (no. 16) 8 days after the last dose of
IFN-ab and in a second patient (no. 10) I month and 2
months after cessation of treatment. Antibodies had been
found in this patient (no. 10) during IFN-m:b maintenance
therapy previously (see Table II).
All samples which were positive for antibody in the ELISA
were tested for neutralising antibody in the virus growth
inhibition assay with both natural human leucocyte IFN-a
and IFNa.b. Among patients who were receiving IFN-a2b,
neutralising antibody was detected in seven samples from six
patients (Table III). Serum from two of these patients [no. 9
(first sample) and no. 11] were positive for antibodies on the
day designated the date of relapse. Despite the presence of
neutralising antibody to IFN-ac2b in two patients, one was in
CR (no. 12) and the other in PR (no. 13). Subsequent
samples from these two patients taken after a further 4
months and 8 months (no. 12) or 7 months (no. 13) were
negative for neutralising antibodies to both natural IFN-a
and IFN-a2b. Both patients remain in stable remission. The
Table HI Neutralisation of IFN-m, activity by sera from multiple
myeloma patients
Neutralising titre against
Patient no. Isotipe IFN-rL2b Natural IF.Va
gd IgAx 20 1.280
-ve 20
1OPC IgGic -ve 20
11 IgDA 20 40
12' IgGK 160 -ve
13b BJK 160 20
14 Non-secretory 320 320
15 IgGx 640 320
All samples taken from patients in PD except for: apatient in CR;
bpatients in PR. cSample taken 1 month after last dose of IFN-a2b.
'Samples taken at 5 and 7 months of IFN-m2 treatment.
remaining two patients (nos. 14 and 15) had been maintained
on IFN-a:b for 11 months since the diagnosis of PD. One
patient (no. 15) had received low doses of melphalan at the
onset of PD before starting a second course of IFN-a2b. In
five samples of serum, the antiviral effect of both natural
human leucocyte IFN-a and IFN-a2b was inhibited. In the
sixth patient (no. 12), antibody to IFN-a-b was found. but
not to natural human leucocyte IFN-a (Table III). In one
patient (no. 9) who had activity against both sources of
IFN-a, the antibody titre against natural IFN-z was greater
than that against IFN-a,t but antibody to IFN-a:b was not
detectable in a sample taken 2 months later.
Among patients who were not receiving IFN-a:b. neutralis-
ing antibody to natural IFN-a (but not IFN-12b) was de-
tected 1 month after cessation of treatment in one patient
(no. 10). In a sample taken 2 months after treatment no
antibody was detected to either IFN-a (Table III). This
patient has remained in PR.
To determine the nature of neutralising antibody in
patients' serum, goat anti-human IgG or IgM was equilib-
rated with sera at a dilution of 1:20 from all patients who
were positive for neutralising antibody before mixing with
IFN-a2b or natural IFN-c. Antibody to human IgG removed
anti-IFN activity, whereas antibody to human IgM had no
effect.
Because other workers have shown that antibodies to
natural human leucocyte IFN-a and IFN-a2b are present in
normal donor serum (Ross et al., 1990), we examined serum
samples from six normal donors and one patient before the
start of maintenance IFN therapy. In no instance were neut-
ralising antibodies detectable in our assay system.
In one patient (no. 14) for whom serum samples have been
available since relapse and who was still receiving IFN-a2b,
the neutralising antibody titre to both natural human leuco-
cyte IFN-a and IFN-a2b was 320 after 9 months of main-
tenance therapy, and this declined to zero as the IFN-ab
course continued and the patient received no other treatment
(Table IV).
In a second patient (no. 9) who was in CR and had no
detectable antibodies in the ELISA in a sample taken after 3
months' IFN-M2b treatment, antibodies were detected in both
assays as therapy continued and the patient entered PD, and
then began to decline with time (Table V).
TableIV Sequential serum samples from patient 14, who is in PD and receivingIFN-azb.
tested for antibodies against IFN-a2
No. and duration
Sample ELISAfor antibodies Neutralising titre against (months) of
no. against IFN-a IFN-m,, Natural IFN-x IFN-m2, courses
I 8.7 U ml-' 320 320 2
5+9
11 NA 20 20 2
5+13
III NA -ve -ve 2
5+16
IV NA -ve -ve 2
5+19
NA. not available.
Table V Sequential serum samples from patient 9, who was in CR and progressed to PD
while receiving IFN-e,. tested for antibodies against IFN-cc.
No. and duration
Sample ELISA for antibodies Neutralising titre against (months) of
no. against IFN-a IFN-. Natural IFN-a IFN-a2b courses
I -ve NA NA I
3
11 <1.0U ml-' 20 1.280 1
5
111 <1.0OUml-' -ve 20 1
7
NA. not available.
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At the Royal Marsden Hospital the use of IFN-a2b as
maintenance therapy in the treatment of multiple myeloma is
increasing because of the encouraging results monitored by
the prolongation of remission in patients who achieve CR
after intensive therapy with HDM,ABMR. Despite the con-
tinuing response of more than 50% of these patients for 4
years, IFN-a,b is not curative. Relapse has occurred in ap-
proximately 30% of patients who achieved CR, and there
appears to be no significant benefit from IFN-a2b main-
tenance therapy in patients who exhibit PR.
In other haematological disorders, neutralising antibodies
have been temporarily associated with a decrease in response
to IFN-a (Figlin & Itri. 1988), particularly among patients
with B-cell disorders (Leavitt et al., 1987; Quesada et al.,
1987; von Wussow et al., 1987; Steis et al., 1988), however
neutralising antibodies have had no effect on clinical outcome
in some trials (Itri et al., 1987; Steis et al., 1991). In chronic
myeloid leukaemia (CML) the development of neutralising
antibodies was associated with relapse or refractoriness to
IFN-a2b (Freund et al., 1989). In a case report, the evolution
of progressive disease in a patient with CML which corre-
sponded to the development of neutralising antibodies to
recombinant IFN-a,b was obviated by changing to human
leucocyte IFN (Freund et al., 1988).
The data in this study show that, despite impairment of
immune function which is associated with multiple myeloma,
62.5% (15 24) of patients who were receiving IFN-a2b at the
time of sampling had antibodies to IFNax, as measured by a
solid-phase ELISA. This unexpectedly high number of
patients who were antibody positive by ELISA was not
confirmed using virus growth inhibition as the end point.
Only 7,19 serum samples which were positive by ELISA had
neutralising antibody. These samples were from six patients
who were receiving IFN-a2b, of whom four were in PD, one
in PR and one in CR, equivalent to 16% of the total patient
population. Despite an increase in tumour mass and para-
protein in the four patients who had PD, immune function
was not abolished since the production of antibody involves
a B-cell response to antigen. Additionally, although the
number of patients with neutralising antibody was small,
there was no indication that patients with myeloma of a
particular isotype were more prone to antibody formation.
Not only did the ELISA fail to predict the presence of
neutralising antibody, but there was no correlation between
the magnitude of the antibody response detected by ELISA
and the neutralising titre. We suggest that a primary screen
using a solid-phase ELISA is of little benefit in predicting
neutralising antibody because of the high number of false
positives encountered in this study. Other workers have
shown that the ability to detect antibody to IFN-a is depen-
dent on the assay system and on the type of recombinant
IFN (Figlin & Itri. 1988; Geysen et al., 1988; Steinmann et
al., 1992). In a study by Spiegel et al. (1986), using an
iodinated radioimmunoassay, a low incidence of antibody
was found in patients given IFN-m2,, suggesting that this
molecule had weak antigenicity. However, comparison of
radioimmunoassay with an enzyme-linked immunoassay sug-
gested that this was probably due to its lower sensitivity (Itnr
et al., 1987).
Although neutralising antibody to IFN-a2b was not
detected in 1:20 dilution in normal donor serum in this
study, the presence of antibody to natural IFN-a., which
cross-reacted with recombinant IFN-2,, IFN-2b and IFN-m2
in serum at the same dilution from 200 normal donors,
prompted Ross et al. (1990) to suggest that autoantibodies
may be a part of normal immune regulation resulting from
exposure to endogenous IFN-a2. Since neutralising antibodies
to natural IFN-x were detected in some patients receiving
IFN-M2b, it cannot be concluded that they resulted from
autoantibody production or because of stimulation of pre-B
cells. Since the stimulation ofmemory B cells should result in
an increasing neutralising titre as therapy continues, the
observation that neutralising antibody was detected tran-
siently in two patients who remain in remission while receiv-
ing IFN-e,b suggests that antibody production does not
involve memory B cells in these patients. Furthermore, the
failure of these antibodies to affect the response in patients in
remission suggests that they have a significantly lower affinity
for ligand than that of ligand for its cellular receptor.
Although multiple myeloma is associated with the presence
of excess plasma cells in the bone marrow, the plasma cell
may not represent the major proliferative compartment. The
presence of idiotypic B lymphocytes in the peripheral circula-
tion (Ruiz-Arguelles et al.. 1984) and the observation that
clonogenic myeloma cells have lymphoplasmacytoid as well
as plasmacytoid morphology in vitro (Millar et al., 1988)
suggest that this compartment may consist of progenitor B
cells that have undergone gene rearrangement. The apparent
failure to evoke a memory B-cell response to IFN-mb in two
patients who remain in remission while receiving the cytokine
suggests either that once B cells had encountered antigen
they failed to be stored as memory B cells or that once stored
they were inhibited from responding to further antigenic
stimulus.
Owing to the immune suppressive nature of multiple mye-
loma, it is unlikely that neutralising antibodies to IFN-a2b
will persist as the disease progresses because of the increase
in the size of the malignant clone concomitant with a
decrease in polyclonal immunoglobulin secretion as a result
of inhibition of normal B-cell development. This is likely to
occur irrespective of whether memory B cells are involved in
the antibody response.
In conclusion, although neutralising antibody to IFN-M2b
was detected in approximately 16% of patients with multiple
myeloma at relapse, it is unlikely that these antibodies were
responsible for the decline in response to IFN-2b, since the
appearance of neutralising antibody was also found tran-
siently in patients who remain in remission and are continu-
ing to receive the cytokine.
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